Lexicon Pharmaceuticals, Inc. (LXRX)

2.24 -0.02 (-0.88%) USD  |  NASDAQ  |  Sep 04, 16:00
2.235 0.00 (0.00%) After-Hours: 20:00
More

Lexicon Pharmaceuticals SG&A Expense (TTM) : 35.34M for June 30, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for LXRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 35.34M
March 31, 2026 34.94M
December 31, 2025 37.32M
September 30, 2025 60.82M
June 30, 2025 92.81M
March 31, 2025 122.65M
December 31, 2024 143.10M
September 30, 2024 143.45M
June 30, 2024 136.09M
March 31, 2024 126.90M
December 31, 2023 113.98M
September 30, 2023 97.70M
June 30, 2023 78.05M
March 31, 2023 58.73M
December 31, 2022 48.08M
September 30, 2022 40.60M
June 30, 2022 35.33M
March 31, 2022 32.58M
December 31, 2021 32.34M
September 30, 2021 29.93M
June 30, 2021 34.62M
March 31, 2021 40.80M
December 31, 2020 47.23M
September 30, 2020 55.36M
June 30, 2020 57.26M
Date Value
March 31, 2020 57.41M
December 31, 2019 56.84M
September 30, 2019 58.83M
June 30, 2019 60.52M
March 31, 2019 63.01M
December 31, 2018 63.75M
September 30, 2018 63.32M
June 30, 2018 64.47M
March 31, 2018 66.19M
December 31, 2017 66.20M
September 30, 2017 64.04M
June 30, 2017 59.58M
March 31, 2017 49.52M
December 31, 2016 43.04M
September 30, 2016 29.08M
June 30, 2016 22.19M
March 31, 2016 20.08M
December 31, 2015 17.39M
September 30, 2015 21.38M
June 30, 2015 20.61M
March 31, 2015 19.46M
December 31, 2014 19.41M
September 30, 2014 18.84M
June 30, 2014 18.93M
March 31, 2014 18.45M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Viatris, Inc. 3.981B
Pfizer Inc. 13.72B
ANI Pharmaceuticals, Inc. 324.76M
Corcept Therapeutics, Inc. 556.47M
Veru, Inc. 16.05M